MEDICINES
PATIENT ASSISTANCE PROGRAMS
IMPORTED MEDICINES
CONTACT US
Upload
Introduction to NAB Celtax 100mg Injection
NAB Celtax 100mg Injection is an anticancer medication used to treat breast cancer, non-small cell lung cancer, ovarian cancer, and AIDS (Acquired Immuno-Deficiency Syndrome). Cancer is characterized by rapid and uncontrolled cell division and growth. This injection may be administered either independently or in conjunction with other anticancer drugs. It is not recommended for individuals with severe liver problems, uncontrolled infection, or low white blood cell or platelet counts.
Usage of this medication is not advised for adolescents and children below the age of 18. Discuss any heart disorders with your doctor before starting this treatment. Serious allergic reactions can result from the administration of this medicine. Employ effective birth control throughout the treatment period and for at least six months after the last dose. It is important to note that this injection may pose harm to individuals dealing with alcoholism, given its alcohol content.
Uses of NAB Celtax 100mg Injection
- Ovarian cancer
- Breast cancer
- Non-small cell lung cancer
- AIDS-related Kaposi’s sarcoma
Therapeutic Effects of NAB Celtax 100mg Injection
NAB Celtax 100mg Injection attaches to the β-tubulin subunits of microtubules, disrupting both interphase (cell growth) and mitotic functions (cell division), thereby impeding the growth of cancer cells.
Interaction of NAB Celtax 100mg Injection with other drugs
Notify your doctor of any prescribed medications, over-the-counter drugs, nutritional and vitamin supplements, or herbal products you are currently taking or have taken before undergoing treatment. Some medications may interact with NAB Celtax 100mg Injection, potentially leading to undesirable side effects.
More Information about NAB Celtax 100mg Injection
- Keep NAB Celtax 100mg Injection out of sight and reach of children.
- Do not store above 25°C.
How to consume NAB Celtax 100mg Injection
A doctor or nurse will administer the NAB Celtax 100mg Injection to you. Do not attempt self-administration. The dose and dosage of the injection will be determined by your doctor.
Safety Advices for NAB Celtax 100mg Injection
Pregnancy
NAB Celtax 100mg Injection can pose a risk to your unborn baby. Inform your doctor if you are pregnant or planning to become pregnant before receiving this injection.
Breast Feeding
Cease breastfeeding during the course of treatment with NAB Celtax 100mg Injection. Consult your doctor for information on potential risks.
Lungs
The suitability of administering NAB Celtax 100mg Injection to patients with lung disorders is uncertain. Kindly seek guidance from your physician for more information.
Liver
Patients with severe liver disorders should avoid using NAB Celtax 100mg Injection as it is contraindicated. Notify your doctor if you have any liver disorders before initiating treatment with NAB Celtax 100mg Injection.
Alcohol
Inadvisable to consume alcohol while undergoing NAB Celtax 100mg Injection treatment.
Driving
The alcohol content in NAB Celtax 100mg Injection may impact your driving ability. Refrain from driving if you experience any discomfort.
Side Effects of NAB Celtax 100mg Injection
Side effects are undesirable symptoms induced by medications. While all medications may produce side effects, not everyone experiences them.
Serious:
- Serious allergic reactions (rash, swelling of face, lips, throat, or tongue, trouble breathing, and swallowing)
- Severe diarrhea
- Severe stomach pain
Common:
- Anemia, feeling tired
- Hair loss
- Burning, tingling, or numbness in your feet or hands
- Muscle and joint pain
- Vomiting, nausea
- Mouth or lip sores
- Infections
- Swelling of hands, feet, and face
- Bleeding
- Irritation at the injection site
- Low blood pressure
Word of Advice
Notify the doctor if the patient has allergies to this medication, as well as any liver or heart conditions, and other medications taken for different medical conditions before initiating this treatment. Regular monitoring of liver function, blood pressure, and blood count is advised while on this medication. Refrain from taking this medication if the patient is planning for pregnancy, during pregnancy, or in breastfeeding mothers, as it may have harmful effects on developing babies. Caution is advised regarding activities like driving and handling heavy machinery after taking this medication, as it can impact concentration and alertness.
FAQs
Q 1. 1. Can NAB Celtax 100mg Injection cause hair loss?
Certainly, hair loss is a common side effect of this medication. Notify the doctor if there is an excessive loss of hair.
Q 2. 2. How does NAB Celtax 100mg Injection work?
It operates by disrupting the microtubule structures that facilitate the division and proliferation of cancer cells, thereby impeding the growth of cancerous cells.
Q 3. 3. Does NAB Celtax 100mg Injection cause liver problems?
Indeed, this medication is not recommended for patients with severe liver disorders. It is essential to inform the doctor before commencing this medication.
Q 4. 4. Can I take NAB Celtax 100mg Injection while driving?
Using this medication while driving is unsafe as it can lead to dizziness, diminished concentration, and alertness.
Q 5. 5. What are the side effects of NAB Celtax 100mg Injection?
The prevalent side effects of NAB Celtax 100mg Injection include anemia, hair loss, numbness in feet or hands, muscle pain, nausea, vomiting, infections, swelling, bleeding, irritation at the injection site, and low blood pressure.
Q 6. 6. Can I take NAB Celtax 100mg Injection during pregnancy?
Taking this medication during pregnancy is unsafe as it can have harmful effects on the developing baby. Inform the doctor if the patient is planning for pregnancy before initiating this medication.
Fact Box of NAB Celtax 100mg Injection
Molecule name: Paclitaxel
Pharmacological class: Anti-Neoplastics
Therapeutic class: Anti-Microtubular Agents
indications:
Ovarian cancer
Breast cancer
Non-small cell lung cancer
AIDS-related
Kaposi’s sarcoma
Ovarian cancer
Breast cancer
Non-small cell lung cancer
AIDS-related
Kaposi’s sarcoma
References
- Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Cytotoxic agents, 12th edition, 2011, 1707 – 1709.
- KD Tripathi, Essentials of Medical Pharmacology, Anticancer drugs, 7th edition, 2013, 865.
- Hospira UK Limited, Electronic medicines compendium (emc), [ Revised on March 2020] [ Accessed on 22nd June 2021],Hospira UK Limited, Electronic medicines compendium (emc), [ Revised on March 2020] [ Accessed on 22nd June 2021], https://www.medicines.org.uk/emc/files/pil.3891.pdf
- Bristol-Myers Squibb Company, US Food and Drug Administration, [ Revised on April 2011] [ Accessed on 22nd June 2021], https://www.accessdata.fda.gov/drugsatfda_docs/lab el/2011/020262s049lbl.pdf
Reviews
There are no reviews yet.